Press Releases Items Per Page 102550 Year None202020192018 07-10-2020 Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 07-07-2020 Akero Therapeutics Announces Pricing of Public Offering of Common Stock 07-06-2020 Akero Therapeutics Announces Proposed Public Offering of Common Stock 06-30-2020 Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients 06-29-2020 Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001 06-17-2020 Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH 06-10-2020 Akero Therapeutics Appoints Tom Heyman to its Board of Directors 05-26-2020 Akero Therapeutics To Present At The Jefferies Virtual Healthcare Conference 05-13-2020 Akero Therapeutics Reports First Quarter 2020 Financial Results 03-31-2020 All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 14
07-10-2020 Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
06-30-2020 Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
